Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotigotine for Apathy in De Novo Parkinson's Disease
NCT02786667Phase 3Unknown
- Sponsor
- CHU Grenoble Alpes
- Start
- Jun 2012
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Rotigotine with Placebo (2 arms). Primary endpoint: Lille Apathy Rating Scale at 6 months. Status: unknown.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02786667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02786667.